RELMADA THERAPEUTICS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$59.1M | -$83.9M | -$103.7M | -$161.2M | -$125.7M |
| Operating expenses | $59.1M | $83.9M | $103.7M | $161.2M | $125.7M |
| Cash from operations | -$45.8M | -$51.8M | -$51.7M | -$103.8M | -$91.9M |
| Total assets | $94.0M | $45.8M | $97.6M | $152.9M | $223.3M |
| Total liabilities | $7.5M | $10.3M | $12.2M | $12.5M | $15.1M |
Shares outstanding 104.9M · Free float 97.4%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.